Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, today announces promising interim results ...

Lipella plans to submit an IND application for a Phase 2b trial and engage in ... debilitating condition. A Phase 2a multicenter, dose-ranging clinical trial is currently underway to evaluate ...

Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral RinsePhase 2a Study Now Fully Enrolled ...

NVDX3 elicited bone formation as early as 12 weeks and functional fusion by 26 weeks in ovine posterolateral fusion (PLF) modelIn phase 1b/2a clinical trial, early bone fusion was observed at 12 ...

Arrowhead Pharmaceuticals, Inc.’s ARWR share price has dipped by 10.49%, which has investors questioning if this is right ...

today announces promising interim results from the BIRCH Phase 2a clinical trial of its lead asset, BIOX-101, to treat intracerebral hemorrhagic stroke (ICH). Interim analysis from the first 16 ...

“With the Phase 2a trial now fully enrolled and final data expected this quarter, we are advancing toward key value-driving milestones, including a Phase 2b IND submission and broader regulatory ...

today announces promising interim results from the BIRCH Phase 2a clinical trial of its lead asset, BIOX-101, to treat intracerebral hemorrhagic stroke (ICH). Interim analysis from the first 16 ...